Subscribe To
LGND / 2 Medical Stocks to Buy Before Earnings
LGND News
By Zacks Investment Research
November 1, 2023
Ligand Pharmaceuticals (LGND) Laps the Stock Market: Here's Why
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day. more_horizontal
By Zacks Investment Research
October 24, 2023
Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre more_horizontal
By Zacks Investment Research
October 20, 2023
Ligand Pharmaceuticals (LGND) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $52.09, denoting a -1.31% change from the preceding trading day. more_horizontal
By Zacks Investment Research
October 9, 2023
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $58.84, indicating a +1.19% shift from the previous trading day. more_horizontal
By Zacks Investment Research
October 9, 2023
Will Ligand (LGND) Beat Estimates Again in Its Next Earnings Report?
Ligand (LGND) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i more_horizontal
By Zacks Investment Research
September 28, 2023
Ligand (LGND) Acquires Certain Assets of Novan for $12.2M
Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform more_horizontal
By Zacks Investment Research
September 19, 2023
Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own more_horizontal
By Seeking Alpha
September 1, 2023
Ligand: Nothing Exciting Stands Out
Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodext more_horizontal